

JOINN Laboratories NEWS

昭衍
JOINN

JOINN Laboratories Hosts the 30th Anniversary Celebration Highlighting Our Original Aspiration and Deriving the Future: Looking Back on the Journey and Drawing a New Blueprint for Development

On August 25, 2025, the 30th anniversary celebration of JOINN Laboratories (China) Co. Ltd. (hereinafter referred to as "JOINN"), was themed "JOINN's Original Aspiration and Deriving the Future". Scientific leaders, experts and colleagues from government departments, industry associations, partners and JOINN gathered together to review the 30-year development history of JOINN and work together to draw a blueprint for future development.

Chairman's Speech

Thank you to the JOINN Team for Supporting the Development of China's Biomedicine Innovation
At the celebration of the 30th anniversary of JOINN, Yuxia Feng, the founder and chairman of the company, delivered a speech, reviewing the journey of the enterprise since its inception in 1995, as the first drug evaluation company in China. Ms. Feng highlighted the early days of JOINN's pathbreaking journey which was supported by national reform and opening up policy, and the support of the experienced review experts. The support allowed enterprises from early stage companies to industry leaders.

Ms. Feng detailed JOINN's innovative breakthroughs:

- In 1997, JOINN undertook the safety evaluation of the world's first gene therapy drug, and subsequently successively won the first safety evaluation work of China's first stem cell, small nucleic acid, CAR-T, bispecific antibody, ADC and other innovative drugs.
 - Over the past 30 years, JOINN undertaken more than 40% of the safety evaluation of China's large - molecule biologics drugs.
 - In the past five years, it has participated in the evaluation of 59% of the marketed large molecule biologics drugs.
 - JOINN has also passed the GLP certification of multiple countries, including the United States, China, Europe, and Japan.
- From 2020 to 2024, JOINN has helped more than 167 new drugs obtain clinical approval from the US FDA, promoting the globalization of China's innovative drugs.



She specially thanked the Government at all levels, industry experts, partners, shareholders, and generations of JOINN people, saying that it was the "favorable timing, geographical and human conditions" that made the development of the enterprise.

In the future, JOINN will continue to adhere to its original aspiration, serve for drug innovation, focus on safety evaluation and monitoring of drugs throughout life cycle, innovate to serve innovation, grow together with biopharmaceutical companies, and continue to contribute to the development of the industry." Ms. Feng's speech was not only a summary of JOINN's 30 years but also conveyed the firm confidence of the enterprise to embark on a new journey.



Important Voices: Empowering Zhaodan's Development and Promoting Industrial Upgrade

Haidong Wu, the Executive President of the China Pharmaceutical Enterprise Management Association and the former Deputy Director of the Department of Consumer Goods Industry of the Ministry of Industry and Information Technology, pointed out that industry associations are the key bridges for coordinating and connecting all parties. The Association will continue to support the development of outstanding enterprises such as JOINN and promote the coordinated progress of the pharmaceutical industry.

Guanhua Du, the Deputy Director of the Institute of Materia Medica of the Chinese Academy of Medical Sciences and a member of the International Eurasian Academy of Sciences, affirmed the breakthroughs of JOINN from the perspective of technological innovation, emphasizing that the expert team will continue to provide guidance for the enterprise, help it keep pace with the times, and contribute more to the development of the industry.

Yufei Liu, the Director of the Biotechnology and Large Health Industry Bureau of the Beijing Economic Technological Development Area Management Committee, said that governments at all levels have always been the solid backing of JOINN. From policy empowerment to environment creation, from industrial layout to resource docking, the government will continue to provide a high quality development environment for the enterprise in the future and strengthen its determination to help the biomedical cause.

Employee Representative: Casting Greatness from the Ordinary and Growing Together with the Enterprise

Jinling Ma, an employee representative, shared her growth story with JOINN on the stage where she started as a newcomer to a team leader. Her personal growth story epitomizes JOINN's support of employee growth from entry level positions to team leadership roles. Ms. Ma quoted "Thirty years, for JOINN people, is the greatness accumulated in countless ordinary days."

Innovation Together - Pioneer Customers Award: Witnessing the Breakthrough of "From 0 to 1" in China's Biomedical Industry

The "Innovation Together - Pioneer Customer" award presented focuses on enterprises that have made key breakthroughs in the field of China's biomedical industry, covering several cutting - edge fields such as gene therapy, stem cell therapy, antibody drug conjugates (ADC), bispecific antibodies, and CAR-T therapies. This honor is not only a recognition of the customers' "first in the world" but also a witness to the mutual trust and mutual achievement between the two parties, allowing innovation to move from the laboratory to the clinic and benefit thousands of patients.



Employee Recognition: Paying Tribute to "JOINN Power" Across Multiple Dimensions

The employee recognition session became an important chapter in conveying the warmth of the enterprise. The celebration had five major awards:

- Pioneering and Opening - Up Award
- Foundation - Laying Breakthrough Award
- Responsibility - Taking Innovation Award
- Tackling Difficulties Award
- New Sharp Potential Building Award

These awards cover the entire life cycle of the enterprise's development from the foundational start up to opening new business fields, and from the core

technology breakthrough to the growth of new forces. These awards pay tribute to the employee groups who have contributed to the enterprise at different stages.

Blueprint Release: Starting from the “Age of 30,” Initiating a New Global Journey

At the milestone of 30 years, JOINN released its future development blueprint. Many technical leaders took the stage to jointly interpret the core of the plan, and Gao Dapeng, the director and general manager of JOINN, summarized:

“After 30 years of hard work, JOINN will always take ‘innovation - serving - innovation’ as its core competitive differentiator, and will continue to use new technologies and tools to upgrade business capabilities and service efficiency. JOINN is committed to practicing the concepts of promoting the globalization of service systems, accelerating the industrialization of scientific research results, and helping the internationalization of the pharmaceutical industry. The companies is committed to growing together with global pharmaceutical companies, and contribute to protecting human health.”



Gratitude for the Company: Joining Hands for the Next 30 Years

At the end of the celebration, the “Gratitude for the Company” session was launched. Representatives from several companies, including 3D Medicine and CanSinoBio, were invited to join the JOINN team to raise the “flag of the future,” which symbolizes cooperation and hope. This symbolizes that all parties will continue to delve into drug research and development, collaborate and innovate, solve industry problems, and help scientific research results to be implemented.

The 30th Anniversary celebration is completed but the new journey of JOINN's team and their partners to protect human health and promote the high-quality development of the biopharmaceutical industry has begun.



昭衍
JOINN